EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real-world Safety and Effectiveness of Neoadjuvant Chemoimmunotherapy in Squamous Cell Lung Cancer: A Retrospective European Multicenter Study

Julio Herrero Colomina, Ana Parreira, Sarah Salih Al-Hamami, María Sereno, Mayra Alejandra Maridueña, Javier Baena, Sofía Silva, Rosario García-Campelo, Federico Monaca, Emilio Bria, Jacobo Rogado, Luis Cabezón-Gutiérrez und 18 weitere

Clinical Lung Cancer · 2026

DOI: 10.1016/j.cllc.2026.07.010 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2026. Verfasst von Julio Herrero Colomina und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester,…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Lung Neoplasms, Carcinoma, Squamous Cell, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Squamous cell lung cancer (SqCLC) accounts for approximately 25% of non-small cell lung cancer (NSCLC). Neoadjuvant chemoimmunotherapy has been established as standard-of-care for resectable NSCLC. Real-world data on safety and effectiveness remain limited. MATERIALS AND METHODS: We conducted a retrospective multicenter cohort study of patients with resectable SqCLC treated with SOC neoadjuvant chemoimmunotherapy across 16 European centers. Primary endpoints were rate of pathological complete response (pCR), major pathological response (MPR), and immune-related adverse events (irAEs) graded per Common Terminology Criteria for Adverse Events v5.0. Secondary endpoints included resection rate and 1-year event-free survival (EFS). RESULTS: Of 127 patients (69.3% male), 88 were stage III (69.3%). They received a median of 3 chemoimmunotherapy cycles, most commonly carboplatin-paclitaxel-nivolumab (72.4%). Dose reductions and treatment discontinuation occurred in 26 (20.5%) and 10 patients (7.9%), respectively. Seventy-nine patients (62.2%) experienced ≥ 1 AE, including 9 grade 3 irAEs. No chemoimmunotherapy‑related deaths occurred. Objective response rate was 76.8%. Twenty-four patients did not undergo surgery, including 4 due to toxicity; subsequently, 9 received radical radiotherapy. Overall (n = 127), pCR and MPR rates were 41.7% and 63.8%, respectively. Among surgical patients (n = 103), pCR was 51.5% and MPR 78.6%. 1-year EFS rate was 75.6%. Notably, 58.3% of patients who did not proceed to surgery experienced disease progression within 1 year and 37.5% died. CONCLUSIONS: In this European real‑world cohort, neoadjuvant chemoimmunotherapy for resectable SqCLC was feasible, demonstrated manageable toxicity, and achieved high pCR rates. These findings support broader implementation in routine practice and further research into predictors of benefit and long‑term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyLung NeoplasmsCarcinoma, Squamous CellAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyCarcinoma, Non-Small-Cell LungHumansRetrospective StudiesMaleFemalePathologic Complete ResponseEuropeMiddle AgedAgedSurvival RatePrognosis

Stichwörter der Autor:innen

Event-free survivalNon-small cell lung cancerReal-world studyResectable diseaseSquamous cell carcinoma

Autor:innen und Institutionen

  • Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK.
  • Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Department of Medical Oncology, Manchester Foundation Trust, Wythenshawe Hospital, Manchester, UK.
  • Department of Medical Oncology, Hospital Universitario Infanta Sofía, Madrid, Spain.
  • Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain.
  • Department of Medical Oncology, Complejo Hospitalario Universitario a Coruña, A Coruña, Spain.
  • Department of Medical Oncology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Zitieren

APA

Colomina, J. H., Parreira, A., Al-Hamami, S. S., Sereno, M., Maridueña, M. A., Baena, J., Silva, S., García-Campelo, R., Monaca, F., Bria, E., Rogado, J., Cabezón-Gutiérrez, L., Bolnykh, I., Newsom-Davies, T., O'Beirne, H., Geldart, T., Johnson, M., Goranov, B., James, L., …, & Gomez-Randulfe, I. (2026). Real-world Safety and Effectiveness of Neoadjuvant Chemoimmunotherapy in Squamous Cell Lung Cancer: A Retrospective European Multicenter Study. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.07.010

Vancouver

Colomina JH, Parreira A, Al-Hamami SS, Sereno M, Maridueña MA, Baena J, et al. Real-world Safety and Effectiveness of Neoadjuvant Chemoimmunotherapy in Squamous Cell Lung Cancer: A Retrospective European Multicenter Study. Clinical Lung Cancer. 2026. doi:10.1016/j.cllc.2026.07.010

BibTeX
@article{Colomina2026,
  author = {Colomina, Julio Herrero and Parreira, Ana and Al-Hamami, Sarah Salih and Sereno, María and Maridueña, Mayra Alejandra and Baena, Javier and Silva, Sofía and García-Campelo, Rosario and Monaca, Federico and Bria, Emilio and Rogado, Jacobo and Cabezón-Gutiérrez, Luis and Bolnykh, Iakov and Newsom-Davies, Tom and O'Beirne, Helen and Geldart, Tom and Johnson, Matthew and Goranov, Bojidar and James, Lijo and Steele, Nicola and Martín, Ana López and Mielgo, Xabier and Gómez, Jenifer and Castro, Natalia and Sequero, Silvia and Collazo, Ana and Aguado, Carlos and Cove-Smith, Laura and Summers, Yvonne and Gomez-Randulfe, Igor},
  title = {Real-world Safety and Effectiveness of Neoadjuvant Chemoimmunotherapy in Squamous Cell Lung Cancer: A Retrospective European Multicenter Study},
  journal = {Clinical Lung Cancer},
  year = {2026},
  doi = {10.1016/j.cllc.2026.07.010}
}
Kostenlos starten →